Acute Lymphoblastic Leukemia Classification

There are several systems of classification of Acute lymphoblastic leukemia. The classification is commonly used to determine treatment and predict the prognosis of the cancer.

French-American-British (FAB) classification

The French-American-British (FAB) classification that was used commonly earlier includes:-

  • L1 – Around 25 to 30% of adult cases and 85% of childhood cases of ALL are of this subtype. In this type small cells are seen with:-
    • regular nuclear shape
    • homogeneous chromatin
    • small or absent nucleolus
    • scanty cytoplasm
  • L2 – Around 70% of adult cases and 14% of childhood cases are of this type. The cells are large and or varied shapes with:-
    • irregular nuclear shape
    • heterogeneous chromatin
    • large nucleolus
  • L3 – This is a rarer subtype with only 1 to 2% cases. In this type the cells are large and uniform with vacuoles (bubble like features) in the cytoplasm overlying the nucleus.

This classification was abandoned by the World Health Organization because the L1 and L2 subtypes could not be differentiated in terms of clinical symptoms, prognosis and genetic abnormalities. The mature B-cell ALL or L3 type is now classified as Burkitt's lymphoma/leukemia.

Revised version of FAB

WHO proposed a classification of ALL that was to be the revised version of the FAB classification. This used the immunophenotypic classification that includes:-

  • Acute lymphoblastic leukemia/lymphoma or formerly L1 and L2 – this has subtypes including:-
    • Precursor B acute lymphoblastic leukemia/lymphoma – this has genetic subtypes including t(12;21)(p12,q22) TEL/AML-1, t(1;19)(q23;p13) PBX/E2A, t(9;22)(q34;q11) ABL/BCR and T(V,11)(V;q23) V/MLL
    • Precursor T acute lymphoblastic leukemia/lymphoma
  • Burkitt's leukemia/lymphoma or formerly L3
  • Biphenotypic acute leukemia

For immunophenotyping and classification of ALL a TdT assay and a panel of monoclonal antibodies for T cell and B cell associated antigens are used.

Immunophenotypic categories of acute lymphoblastic leukemia (ALL)

Types FAB Class Tdt T cell associate antigen B cell associate antigen c Ig s Ig
Precursor B L1,L2 + - + -/+ -
Precursor T L1,L2 + + - - -
B-cell L3 - - + - +

ALL can also present in variant forms or in different forms. This includes ALL with cytoplasmic granules, aplastic form of ALL, ALL with eosinophilia, secondary ALL and relapse of ALL or lymphoblastic leukemia.

Further Reading

Last Updated: Jul 6, 2023

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, July 06). Acute Lymphoblastic Leukemia Classification. News-Medical. Retrieved on July 21, 2024 from

  • MLA

    Mandal, Ananya. "Acute Lymphoblastic Leukemia Classification". News-Medical. 21 July 2024. <>.

  • Chicago

    Mandal, Ananya. "Acute Lymphoblastic Leukemia Classification". News-Medical. (accessed July 21, 2024).

  • Harvard

    Mandal, Ananya. 2023. Acute Lymphoblastic Leukemia Classification. News-Medical, viewed 21 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Dr. Chao Ma: Pioneering 'Leukemia-on-a-Chip' for CAR T Cell Therapy at SLAS 2024